Sonoclot Analyzer, ACT Machine India, Thromboelastography, Cardiac Surgery, Liver Transplant

A-535 2002 Differential Effects of Hirudin and Heparin on the Whole Blood Clot Formation Jaime Torres, M.D.; Nobukazu Sato, M.D.; Kenichi A. Tanaka, M.D.; Fania Szlam, M.M.S.; Jerrold H. Levy, M.D. Anesthesiology, Emory University School of Medicine, Atlanta, Georgia Introduction: Although heparin (Hep) is widely used for anticoagulation during cardiac or vascular surgery, some patients may suffer from serious complications such as heparin-induced thrombocytopenia. Recombinant hirudin (rHir), a direct thrombin inhibitor, is used as a heparin alternative1, 2. However, the effects of rHir on the whole blood clot formation is not completely understood. Therefore, we designed a study to compare the effects of rHir and Hep using the Sonoclot, a viscoelastic coagulation monitor. Methods: After institutional approval and informed consent, 5 healthy volunteers were included in this protocol. Blood samples were collected int...

J Cardiothorac Vasc Anesth. 2008 Oct;22(5):670-4. Epub 2008 Mar 24. Sonoclot analysis in coronary artery surgery: a comparison between patients with unstable coronary artery disease treated with enoxaparin before surgery and patients with stable coronary artery disease not treated with enoxaparin. Pleym H, Wahba A, Bjella L, Stenseth R. Department of Cardiothoracic Anesthesia and Intensive Care, St Olav University Hospital, Trondheim, Norway. hilde.pleym@stolav.no Abstract OBJECTIVES: To investigate whether perioperative Sonoclot analyses could identify differences in hemostatic function between a group of patients with unstable coronary artery disease treated with low-molecular-weight heparin until the evening before surgery and a group of patients with stable coronary artery disease not treated with lowmolecular-weight heparin. DESIGN: Prospective and observational investigation. SETTING: A university hospital, single institution. PARTICIPANTS: Patien...

Sonoclot Analyzer and Platelet Aggregometry Detect Platelet Receptor (GPIIb/IIIa) Blockade Yue Dong, M.D.; Gregory A. Nuttall, M.D.; William C. Oliver, M.D.; Mark H. Ereth, M.D. Anesthesiology, Mayo Clinic, Rochester, Minnesota, United States [Background] Abciximab blocks the major platelet surface receptor (GPIIb/IIIa), which is critical to platelet aggregation. Practical means to monitor platelet function in patients on abciximab undergoing emergency cardiac surgery is needed. [Methods] After Institutional Review Board approval and informed consent, blood samples were drawn from 20 healthy volunteers. Celite activated Sonoclot analysis and ADP activated Platelet Poor Plasma (PRP) aggregometry were completed after addition of abciximab. The Sonoclot analysis and ADP activated PRP aggregometry were used to detect platelet function. The data was analyzed by student's t test and P<0.05 is statistically significan...